AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3602025
Drug: Alizapride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride (5 mg/kg/day, oral route)
Trial: 3602025
Drug: Alizapride (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride (intravenous and oral routes)
Trial: 23401447
Drug: Elesclomol 213
RxNorm normalized name: Élesclomol
DrugBank: Elesclomol (DB05719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elesclomol 213 mg/m2 plus paclitaxel 80 mg/m2
Trial: 23401447
Drug: Paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m2 alone
Trial: 8087352
Drug: Nasal and
RxNorm normalized name: Nasal and Sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal and oral endotracheal intubation with gastric intubation performed via the same route in Group 1 patients
Trial: 2767860
Drug: B subunit‐killed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B subunit‐killed whole cell (BS‐WC) oral cholera vaccine
Trial: 2767860
Drug: Killed whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed whole cell‐only (WC) oral cholera vaccine
Trial: 1221432
Drug: delta9-THC (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delta9-THC (25 mg)
Trial: 1221432
Drug: CBN (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBN (50 mg)
Trial: 1221432
Drug: delta9-THC (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delta9-THC (25 mg) + CBN (50 mg)
Trial: 23429495
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg subcutaneously twice weekly with gemcitabine
Trial: 15534159
Drug: Nortriptyline combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline combined with transdermal nicotine (nortriptyline started at 25 mg, titrated to 75 mg/d for 12 weeks; transdermal nicotine at 21 mg/d for 8 weeks)
Trial: 11575536
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (50 mg/kg bolus followed by 15 mg x kg(‐1) x h(‐1) for 6 h)
Trial: 7810638
Drug: Acipimox (antilipolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (antilipolytic agent)
Trial: 786686
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate (45 mg Zn++) with tetracycline hydrochloride (500 mg)
Trial: 786686
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate (45 mg Zn++) with doxycycline chloride (200 mg)
Trial: 31004853
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including intravenous, topical, and combined)
Trial: 23200272
Drug: TMZ 140
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ 140 mg/d
Trial: 23200272
Drug: TMZ 70
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ 70 mg/d
Trial: 23200272
Drug: TMZ 140
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ 140 mg/d and TMZ 70 mg/d
Trial: 14512806
Drug: Rye bran
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rye bran bread (295 g daily)
Trial: 14512806
Drug: Wheat bread
RxNorm normalized name: Nutritional Supplement Oral Food, Solid [DIETARY SPECIALTIES WHEAT BREAD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bread (275 g daily, control)
Trial: 1651893
Drug: Rebamipide 300
RxNorm normalized name: Rébamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Rebamipide 300 mg/day orally for 7 days
Trial: 1651893
Drug: Rebamipide 10
RxNorm normalized name: Rebamipide 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide 10 mg/kg, i.v.
Trial: 1651893
Drug: Rebamipide 10
RxNorm normalized name: Rebamipide 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide 10 mg/kg/hr, i.v.
Trial: 1651893
Drug: Rebamipide (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide (10, 30, 100, 300 mg/kg, i.p.)
Trial: 26087303
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) plus usual care (UC)
Trial: 21527577
Drug: High red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High red meat diet (420 g/d)
Trial: 21527577
Drug: Low red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low red meat diet (60 g/d)
Trial: 11101476
Drug: Vegetarian diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetarian diet (0 g/d)
Trial: 21527577
Drug: Medium red
RxNorm normalized name: Loreal 5RB Medium Reddish Brown Hair Color
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium red meat diet (120 g/d)
Trial: 14652358
Drug: Sodium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium supplementation (NaSp) treatment (120 mmol Na+/d)
Trial: 1512151
Drug: Hyperthermia twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermia twice a week (57.8% complete response rate)
Trial: 1512151
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (56.3% complete response rate)
Trial: 17330831
Drug: Metformin (1700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1700 mg/day)
Trial: 22119204
Drug: ADT+DE (androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT+DE (androgen deprivation therapy + docetaxel-estramustine)
Trial: 22119204
Drug: Chemotherapy (docetaxel-estramustine)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (docetaxel-estramustine)
Trial: 15755856
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate supplementation (1000 mg Ca/d)
Trial: 12149511
Drug: Saliva IgM
RxNorm normalized name: Dunaliella salina extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saliva IgM and IgA antibodies to E. coli O157 lipopolysaccharide (LPS)
Trial: 26275735
Drug: Chemoradiotherapy (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (3 cycles of neoadjuvant chemotherapy: 100 mg/m² cisplatin and 85 mg/m² docetaxel followed by radiotherapy with 44 Gy in 22 fractions over 3 weeks)
Trial: 23242470
Drug: pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pimecrolimus cream 1%
Trial: 23242470
Drug: mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mometasone furoate (1 mg/g)
Trial: 21319944
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg and esomeprazole magnesium 20 mg fixed-dose combination (FDC) twice daily for 12 months
Trial: 17126628
Drug: Caloric beverage
RxNorm normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caloric beverage (increased portion size from 360 g/12 fl oz to 540 g/18 fl oz)
Trial: 8472523
Drug: Meclofenamic acid
RxNorm normalized name: Meclofenamic Acid
DrugBank: Meclofenamic acid (DB00939)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclofenamic acid (200 mg b.i.d.)
Trial: 3718377
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg scopolamine
Trial: 3718377
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg scopolamine with 5 mg d-amphetamine
Trial: 3718377
Drug: Scopolamine and
RxNorm normalized name: butylscopolamine and analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine and scopolamine with d-amphetamine (after discontinuation on day 5)
Trial: 27261817
Drug: ZP‐025 (Monurelle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZP‐025 (Monurelle Biogel®) vaginal gel, 1 or 2 times/daily intra‐vaginally for about 23 intermenstrual days
Trial: 27261817
Drug: ZP‐025 (Monurelle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZP‐025 (Monurelle Biogel®) vaginal gel
Trial: 27261817
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment, lubricants on demand allowed)
Trial: 22755467
Drug: Sequential practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential practice (implicit first and then explicit)
Trial: 21084037
Drug: Tacrolimus 0.1%
RxNorm normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.1% ointment (FK506)
Trial: 21084037
Drug: Methylprednisolone aceponate
RxNorm normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone aceponate ointment (MPA)
Trial: 21084037
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (MPA + FK506)
Trial: 18295469
Drug: levobupivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 0.125% with fentanyl 1 microg/mL at 8 mL/h
Trial: 18295469
Drug: bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.125% with fentanyl 1 microg/mL at 8 mL/h
Trial: 18295469
Drug: ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.2% with fentanyl 1 microg/mL at 8 mL/h
Trial: 11936565
Drug: Immediate-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release formulation (500 mg IR)
Trial: 11936565
Drug: Modified-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release formulation (500 mg MR)
Trial: 11936565
Drug: Modified-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release formulation (750 mg MR)
Trial: 2140331
Drug: Josamycin 500
RxNorm normalized name: josamycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Josamycin 500 mg three times daily
Trial: 6815790
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methylprednisolone (control)
Trial: 6238861
Drug: C 48.401‐Ba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C 48.401‐Ba cream (0.05% halomethasone)
Trial: 6238861
Drug: Ointment containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment containing 0.05% halomethasone
Trial: 6238861
Drug: Ointment containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment containing 0.1% betamethasone valerate
Trial: 6238861
Drug: C 48.401‐Ba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C 48.401‐Ba ointment (0.05% halomethasone)
Trial: 27548106
Drug: Pulsatile cortisol
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile cortisol infusion
Trial: 27548106
Drug: Mifepristone (GR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (GR antagonist)
Trial: 27548106
Drug: Eplerenone (MR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (MR antagonist)
Trial: 27548106
Drug: Withdrawal vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal vs addback of sex steroids
Trial: 19268928
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clomiphene citrate (25 mg/day) and vitamin E (400 mg/day)
Trial: 19268928
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clomiphene citrate and vitamin E
Trial: 16115336
Drug: Danish meat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danish meat diet (60 g of pork meat)
Trial: 16115336
Drug: Polish meat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polish meat diet (60 g of pork meat)
Trial: 10026394
Drug: UVA irradiation
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA irradiation at low dose (20 J/cm2)
Trial: 10026394
Drug: UVA irradiation
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA irradiation at high dose (60 J/cm2)
Trial: 10026394
Drug: UVA irradiation
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA irradiation (both doses)
Trial: 7473528
Drug: Phosphoramidon (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphoramidon (combined inhibitor of endothelin converting enzyme and neutral endopeptidase)
Trial: 7473528
Drug: Thiorphan (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiorphan (selective inhibitor of NEP)
Trial: 30022753
Drug: rhTPO +
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTPO + DXM treatment
Trial: 30022753
Drug: DXM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DXM treatment
Trial: 22380743
Drug: (R)-warfarin
DrugBank: (S)-Warfarin (DB14055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-warfarin
Trial: 22380743
Drug: (S)-warfarin
RxNorm normalized name: (S)-Warfarin
DrugBank: (S)-Warfarin (DB14055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-warfarin
Trial: 22380743
Drug: Protein binding
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein binding of (R)- and (S)-warfarin
Trial: 17213239
Drug: Assertive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive therapy (standing on the fractured limb and walking in parallel bars)
Trial: 17213239
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (immobilization under skin traction and gradual use of a wheelchair)
Trial: 11244392
Drug: Focused short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Focused short-term group therapy (10 sessions of 1.5 hours per week)
Trial: 11244392
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received group therapy 5 months after the first group)
Trial: 9227716
Drug: Pre-inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-inhalation of LTD4
Trial: 9227716
Drug: Pre-inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-inhalation of methacholine
Trial: 7678684
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 mg b.i.d. titrated to 75 mg)
Trial: 7678684
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR (120 mg q.d. titrated to 360 mg)
Trial: 2889081
Drug: Intramuscular recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular recombinant alpha 2‐interferon (r‐IFN) ('Roferon') 10 X 10(6) IU/m2 thrice weekly for 12 weeks
Trial: 28521579
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) - 8 weekly sessions
Trial: 19399268
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (cetrorelix 0.25 mg/day) until the day of hCG administration (Group A, 66 cycles)
Trial: 19399268
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (cetrorelix 0.25 mg/day) until the day before hCG administration (Group B, 26 cycles)
Trial: 16890670
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg toremifene
Trial: 14728938
Drug: HIT-91 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HIT-91 therapy
Trial: 14521705
Drug: 5% coal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% coal tar ointment
Trial: 8811478
Drug: Supplementary surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary surgery or chemotherapy
Trial: 1529416
Drug: Pinacidil 12.5
RxNorm normalized name: pinacidil 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil 12.5 mg
Trial: 15020520
Drug: Pinacidil 25
RxNorm normalized name: pinacidil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil 25 mg
Trial: 3908727
Drug: S6472 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S6472 (750 mg, 2 times/day)
Trial: 3908727
Drug: Cefaclor (CCL)
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor (CCL) (500 mg, 3 times/day)
Trial: 3908727
Drug: Cephalexin (CEX)
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (CEX) (500 mg, 4 times/day)
Trial: 30675739
Drug: levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levomilnacipran ER (40, 80, or 120 mg/d)
Trial: 25363118
Drug: Reality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reality therapy
Trial: 23102380
Drug: Bivalirudin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin + Gp IIb/IIIa inhibitor (tirofiban)
Trial: 23102380
Drug: UFH +
RxNorm normalized name: Unfractionated Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UFH + Gp IIb/IIIa inhibitor (tirofiban)
Trial: 16519386
Drug: Standard Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Propofol (average particle size 193.3 nm) with 2 ml NaCl 0.9%
Trial: 16519386
Drug: Standard Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Propofol (average particle size 193.3 nm) with 2 ml lidocaine 2%
Trial: 16519386
Drug: Small particle
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small particle size lipid emulsion of Propofol (Anepol: average particle size 140.5 nm) with 2 ml NaCl 0.9%
Trial: 16519386
Drug: Small particle
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small particle size lipid emulsion of Propofol (Anepol: average particle size 140.5 nm) with 2 ml lidocaine 2%
Trial: 10356941
Drug: Vitamin supplement
RxNorm normalized name: Vitamin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin supplement (Vitality Roeder 2000 Junior)
Trial: 7644858
Drug: High titre
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High titre vaccines
Trial: 4030162
Drug: Morning dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dose (7:00 a.m.)
Trial: 4030162
Drug: Evening dose
RxNorm normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dose (7:00 p.m.)
Trial: 29747311
Drug: Paclitaxel for
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel for injection (albumin bound) (PAB)
Trial: 29747311
Drug: Paclitaxel for
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel for injection (albumin bound) (PAB) as first-line therapy
Trial: 29747311
Drug: Paclitaxel for
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel for injection (albumin bound) (PAB) as non-first-line therapy
Trial: 29747311
Drug: Paclitaxel for
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel for injection (albumin bound) (PAB) in taxane-naïve patients
Trial: 29747311
Drug: Paclitaxel for
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel for injection (albumin bound) (PAB) in taxane-pretreated patients
Trial: 29747311
Drug: Abraxane (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abraxane (reference drug)
Trial: 23740477
Drug: 120 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/day Eleutherococcus senticosus root extract (ES)